SERPINA1 and ELA2 polymorphisms are not associated with COPD or lung cancer

Lindsey Enewold, Leah E. Mechanic, Elise D. Bowman, Elizabeth A. Platz, Anthony J. Alberg

Research output: Contribution to journalArticle

Abstract

Background: Through their roles in tissue remodeling, variants in the genes that encode alpha1-antitrypsin (AAT) and neutrophil elastase (NE) were hypothesized to be associated with the risk of both chronic obstructive pulmonary disease (COPD) and non-small cell lung cancer (NSCLC). Materials and Methods: Cases with prevalent COPD (n=145), incident NSCLC (n=203) or prevalent COPD plus NSCLC (n=118) were compared to disease-free controls (n=317), to assess two functional polymorphisms in serpin peptidase inhibitor, clade A, member 1 (SERPINA1), which encodes AAT, and eleven tagging polymorphisms in and around elastase 2 (ELA2), which encodes NE. All analyses were stratified by race. Results: Among African-Americans, the less efficient SERPINA1 variant appeared to be associated with increased risk of prevalent COPD but only in the presence of NSCLC (odds ratio=7.39; 95% confidence interval=1.03-53.21) and not after correcting for multiple comparisons. Conclusion: Variations in SERPINA1 and ELA2 were not consistently or strongly associated with the risk of either COPD or NSCLC in either race.

Original languageEnglish (US)
Pages (from-to)3923-3928
Number of pages6
JournalAnticancer research
Volume32
Issue number9
StatePublished - Sep 2012

Keywords

  • Alpha1 antitrypsin
  • Case-control
  • Chronic bronchitis
  • Emphysema
  • Gene polymorphism
  • Lung cancer
  • Neutrophil elastase
  • SNPs

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'SERPINA1 and ELA2 polymorphisms are not associated with COPD or lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Enewold, L., Mechanic, L. E., Bowman, E. D., Platz, E. A., & Alberg, A. J. (2012). SERPINA1 and ELA2 polymorphisms are not associated with COPD or lung cancer. Anticancer research, 32(9), 3923-3928.